ライフサイエンスコーパス: anagrelide

1 ned (91 to ropeginterferon alfa-2b and 83 to anagrelide).

2 ng agents, recombinant interferon alpha, and anagrelide.

3 A standard second-line agent has been anagrelide.

4 ons for the monitoring of patients receiving anagrelide.

5 Hydroxyurea (62.8%) and anagrelide (35.4%) were the primary agents used to treat

6 re was no significant difference between the anagrelide and hydroxyurea group regarding incidences of

7 erferon or pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreducti

8 erferon or pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or observation wi

9 Anagrelide as a selective platelet-lowering agent is not

10 ion system, the efficacy and tolerability of anagrelide compared with hydroxyurea were investigated i

11 curred in 24 (30%) of 80 participants in the anagrelide group and 13 (14%) of 91 participants in the

12 s occurred in 27 (34%) of 80 patients in the anagrelide group and 21 (23%) of 91 patients in the rope

13 occurred in four (5%) of 80 patients in the anagrelide group but was not observed in the ropeginterf

14 group and 44 (53%) of 83 participants in the anagrelide group were female.

15 In the anagrelide group, the most frequent grade 3 or worse adv

16 ompared with five (6%) of 80 patients in the anagrelide group.

17 red with five (6%) of 83 participants in the anagrelide group.

18 ety of ropeginterferon alfa-2b compared with anagrelide in patients with essential thrombocythaemia w

19 ll performance by hydroxyurea, compared with anagrelide, in a recent randomized study.

20 Anagrelide is a novel platelet-lowering agent that has r

21 oncluded that long-term treatment of ET with anagrelide is associated with decreased reporting of ini

22 younger patients; both hydroxycarbamide and anagrelide might be given to patients ineligible for peg

23 effectively lowered by treatment with either anagrelide or hydroxyurea.

24 n hemoglobin levels in patients treated with anagrelide (P < .0001), but not in those receiving hydro

25 thrombosis, in patients with ET treated with anagrelide plus aspirin compared to hydroxyurea plus asp

26 developed increased bone marrow reticulin on anagrelide showed regression of fibrosis when switched t

27 e specimens in patients randomly assigned to anagrelide showed significantly greater increases in ret

28 assigned (1:1) to ropeginterferon alfa-2b or anagrelide, stratified by platelet count, symptom score,

29 nsitive to therapy with hydroxyurea, but not anagrelide, than those without the JAK2 mutation.

30 33 responding patients, 27 (82%) remained on anagrelide therapy for a median of 10.8 years (range, 7

31 These data suggest that patients receiving anagrelide therapy should undergo surveillance bone marr

32 tients (17 to 48 years) with ET who received anagrelide treatment before 1992.

33 n additional information regarding long-term anagrelide use.

34 Confirmatory proof of the noninferiority of anagrelide was achieved after 6 months using the primary

35 Anagrelide was orally dosed according to the US Food and

36 Anagrelide was used in place of hydroxyurea in two patie